• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

适配体:用于生物医学研究的多功能分子。

Aptamers: multifunctional molecules for biomedical research.

机构信息

Biology Department, Indian Institute of Science Education and Research (IISER), 900 NCL Innovation Park, Dr. Homi Bhabha Road, Pune, 411008, India,

出版信息

J Mol Med (Berl). 2013 Dec;91(12):1333-42. doi: 10.1007/s00109-013-1085-2. Epub 2013 Sep 18.

DOI:10.1007/s00109-013-1085-2
PMID:24045702
Abstract

Aptamers are single-stranded oligonucleotides that fold into well-defined three-dimensional shapes, allowing them to bind their targets with high affinity and specificity. They can be generated through an in vitro process called "Systemic Evolution of Ligands by Exponential Enrichment" and applied for specific detection, inhibition, and characterization of various targets like small organic and inorganic molecules, proteins, and whole cells. Aptamers have also been called chemical antibodies because of their synthetic origin and their similar modes of action to antibodies. They exhibit significant advantages over antibodies in terms of their small size, synthetic accessibility, and ability to be chemically modified and thus endowed with new properties. The first generation of aptamer drug "Macugen" was available for public use within 25 years of the discovery of aptamers. With others in the pipeline for clinical trials, this emerging field of medical biotechnology is raising significant interest. However, aptamers pose different problems for their development than for antibodies that need to be addressed to achieve practical applications. It is likely that current developments in aptamer engineering will be the basis for the evolution of improved future bioanalytical and biomedical applications. The present review discusses the development of aptamers for therapeutics, drug delivery, target validation and imaging, and reviews some of the challenges to fully realizing the promise of aptamers in biomedical applications.

摘要

适配子是单链寡核苷酸,可折叠成具有明确三维形状的分子,使其能够与靶标高亲和力和特异性结合。它们可以通过称为“指数富集的配体系统进化”的体外过程产生,并应用于特定的检测、抑制和表征各种目标,如小分子有机和无机分子、蛋白质和整个细胞。由于其合成来源和与抗体相似的作用模式,适配子也被称为化学抗体。与抗体相比,它们具有明显的优势,如体积小、合成可及性以及能够进行化学修饰,从而具有新的特性。第一代适配体药物“Macugen”在发现适配体后的 25 年内就可供公众使用。随着其他药物进入临床试验阶段,这个新兴的医疗生物技术领域引起了极大的兴趣。然而,适配体在开发过程中面临的问题与抗体不同,需要解决这些问题才能实现实际应用。当前适配体工程的发展很可能为未来生物分析和生物医学应用的改进奠定基础。本文综述了适配体在治疗、药物输送、靶标验证和成像方面的发展,并讨论了在充分实现适配体在生物医学应用中的潜力方面所面临的一些挑战。

相似文献

1
Aptamers: multifunctional molecules for biomedical research.适配体:用于生物医学研究的多功能分子。
J Mol Med (Berl). 2013 Dec;91(12):1333-42. doi: 10.1007/s00109-013-1085-2. Epub 2013 Sep 18.
2
Antibodies are challenged.抗体受到挑战。
Indian J Med Sci. 2010 Mar;64(3):144-7.
3
Chimeric aptamers in cancer cell-targeted drug delivery.嵌合适体在癌细胞靶向药物递送中的应用。
Crit Rev Biochem Mol Biol. 2011 Dec;46(6):459-77. doi: 10.3109/10409238.2011.614592. Epub 2011 Sep 28.
4
SELEX Modifications and Bioanalytical Techniques for Aptamer-Target Binding Characterization.SELEX 修饰和适体-靶标结合特性的生物分析技术。
Crit Rev Anal Chem. 2016 Nov;46(6):521-37. doi: 10.1080/10408347.2016.1157014. Epub 2016 Mar 15.
5
Recent developments in protein and cell-targeted aptamer selection and applications.近期蛋白质和细胞靶向适体选择与应用的进展。
Curr Med Chem. 2011;18(27):4117-25. doi: 10.2174/092986711797189619.
6
Application of aptamers for targeted therapeutics.适体在靶向治疗中的应用。
Arch Immunol Ther Exp (Warsz). 2013 Aug;61(4):255-71. doi: 10.1007/s00005-013-0227-0. Epub 2013 Apr 7.
7
Aptamers: a new class of oligonucleotides in the drug discovery pipeline?适体:药物研发流程中的一类新型寡核苷酸?
Curr Opin Pharmacol. 2009 Oct;9(5):602-7. doi: 10.1016/j.coph.2009.07.006. Epub 2009 Aug 28.
8
[Advances in the study of aptamer-based drug for targeting therapy].[基于适配体的靶向治疗药物研究进展]
Yao Xue Xue Bao. 2016 Jul;51(7):1068-76.
9
Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application.适配体:治疗应用的化学性质和修饰的综述。
Molecules. 2019 Nov 21;24(23):4229. doi: 10.3390/molecules24234229.
10
Selection and Application of Aptamers and Intramers.适体和内体的选择与应用。
Adv Exp Med Biol. 2016;917:241-58. doi: 10.1007/978-3-319-32805-8_11.

引用本文的文献

1
Computational Frontiers in Aptamer-Based Nanomedicine for Precision Therapeutics: A Comprehensive Review.基于适配体的纳米医学用于精准治疗的计算前沿:综述
ACS Omega. 2024 Jun 10;9(25):26838-26862. doi: 10.1021/acsomega.4c02466. eCollection 2024 Jun 25.
2
Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications.适体和纳米抗体作为 SARS-CoV-2 诊断和治疗系统应用的新型生物探针。
Biosensors (Basel). 2024 Mar 15;14(3):146. doi: 10.3390/bios14030146.
3
Aptamer functionalized nucleic acid nano drug for targeted synergistic therapy for colon cancer.

本文引用的文献

1
Coupling Aptamers to Short Interfering RNAs as Therapeutics.将适配体与短干扰RNA偶联作为治疗手段。
Pharmaceuticals (Basel). 2011 Oct 27;4(11):1434-1449. doi: 10.3390/ph4111434.
2
Aptamers for Targeted Drug Delivery.用于靶向给药的适配体。
Pharmaceuticals (Basel). 2010 May 27;3(6):1761-1778. doi: 10.3390/ph3061761.
3
Myeloid derived suppressor cells: Targets for therapy.髓源性抑制细胞:治疗靶点
适配体功能化核酸纳米药物用于结肠癌的靶向协同治疗。
J Nanobiotechnology. 2023 Jun 7;21(1):182. doi: 10.1186/s12951-023-01941-z.
4
Aptamer-based nanointerferometer enables amplification-free ultrasensitive detection and differentiation of SARS-CoV-2 variants.基于适配体的纳米干涉仪实现了无需扩增的 SARS-CoV-2 变体超灵敏检测和区分。
Anal Chim Acta. 2023 Jun 15;1260:341207. doi: 10.1016/j.aca.2023.341207. Epub 2023 Apr 11.
5
Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care.用于即时护理治疗药物监测的电化学卡马西平适体传感器
ACS Omega. 2022 Oct 17;7(43):39097-39106. doi: 10.1021/acsomega.2c04865. eCollection 2022 Nov 1.
6
Aptamer Selection Based on Microscale Electrophoretic Filtration Using a Hydrogel-Plugged Capillary Device.基于微尺度电泳过滤的水凝胶塞毛细管装置的适体选择。
Molecules. 2022 Sep 8;27(18):5818. doi: 10.3390/molecules27185818.
7
Current Advances in Aptamer-based Biomolecular Recognition and Biological Process Regulation.基于适体的生物分子识别与生物过程调控的当前进展
Chem Res Chin Univ. 2022;38(4):847-855. doi: 10.1007/s40242-022-2087-9. Epub 2022 May 7.
8
Aptamer Applications in Neuroscience.适体在神经科学中的应用。
Pharmaceuticals (Basel). 2021 Dec 3;14(12):1260. doi: 10.3390/ph14121260.
9
RNA Therapeutics - Research and Clinical Advancements.RNA疗法——研究与临床进展
Front Mol Biosci. 2021 Sep 22;8:710738. doi: 10.3389/fmolb.2021.710738. eCollection 2021.
10
Beyond G-Quadruplexes-The Effect of Junction with Additional Structural Motifs on Aptamers Properties.超越 G-四链体-连接其他结构模体对适体性质的影响。
Int J Mol Sci. 2021 Sep 14;22(18):9948. doi: 10.3390/ijms22189948.
Oncoimmunology. 2013 Apr 1;2(4):e24117. doi: 10.4161/onci.24117.
4
Investigating the malleability of RNA aptamers.研究 RNA 适体的可塑性。
Methods. 2013 Sep 15;63(2):178-87. doi: 10.1016/j.ymeth.2013.03.016. Epub 2013 Mar 25.
5
Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics.用于生物标志物发现、诊断和治疗的高度多重化蛋白质组学平台。
Adv Exp Med Biol. 2013;735:283-300. doi: 10.1007/978-1-4614-4118-2_20.
6
In vivo SELEX for Identification of Brain-penetrating Aptamers.体内 SELEX 技术用于鉴定脑穿透适体。
Mol Ther Nucleic Acids. 2013 Jan 8;2(1):e67. doi: 10.1038/mtna.2012.59.
7
An electronic channel switching-based aptasensor for ultrasensitive protein detection.一种基于电子通道切换的适体传感器,用于超灵敏蛋白质检测。
Anal Chim Acta. 2013 Jan 3;758:130-7. doi: 10.1016/j.aca.2012.10.019. Epub 2012 Oct 23.
8
Therapeutic RNA aptamers in clinical trials.临床研究中的治疗性 RNA 适体。
Eur J Pharm Sci. 2013 Jan 23;48(1-2):259-71. doi: 10.1016/j.ejps.2012.10.014. Epub 2012 Nov 7.
9
Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.靶向血管性血友病因子作为一种新型抗血小板治疗方法;应用抗 vWF 适体 ARC1779 对抗血栓风险。
Arch Pharm Res. 2012 Oct;35(10):1693-9. doi: 10.1007/s12272-012-1000-3.
10
Current progress of RNA aptamer-based therapeutics.基于 RNA 适体的治疗方法的最新进展。
Front Genet. 2012 Nov 2;3:234. doi: 10.3389/fgene.2012.00234. eCollection 2012.